Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

Fiona Powrie © Thomas S. G. Farnetti Wellcome

Wellcome is a global charitable foundation that funds thousands of researchers. It works with academia, philanthropy, businesses, governments, civil society and the public around the world to support science's role in solving health challenges.

With a background in immunology and translational research, Fiona has been a member of Wellcome's Board of Governors since January 2018. She will take up her post in January 2022 from Professor Mike Ferguson, who is stepping down from the Board and Wellcome after 10 years.

Following her appointment, Fiona said: "It is an honour and privilege to serve Wellcome as Deputy Chair. It's an organisation that I've always admired from the beginning of my career. I look forward to working with everyone at Wellcome to help deliver our new strategy that harnesses science and research to improve health for all."

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website

Similar stories

Oxford University wins prestigious Queen’s Anniversary Prize

Her Majesty The Queen has approved the award of The Queen’s Anniversary Prizes to twenty-one higher and further education institutions, including Oxford University, in the most recent round of the independently reviewed scheme. This prestigious award is the highest national honour available to universities and FE colleges across the UK.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

One high altitude explorer acknowledges another

NASA Astronaut and Physiologist Dr Jessica Meir unveils The Physiological Society blue plaque in honour of fellow pioneering Physiologist and Scientific Explorer Mabel FitzGerald.